The available evidence suggests that SARS-CoV2 infection may result in specific damage to the RM and other organ systems. This acute pathology to the RM in patients with COVID-19 is likely further compounded by underlying health conditions, effects of MV, and other COVID-19 pathology that impairs RM performance and increases breathing work. These factors combined may explain the acute and persistent dyspnoea and other functional limitations demonstrated in patients with COVID-19.
The role and efficacy of RMT in improving dyspnoea and other key functional outcomes are well-established for patients across multiple health conditions. Due to the direct impact of SARS-CoV2 infection on RM performance, it is becoming apparent that RM testing and RMT will play a key role in the rehabilitation of patients with COVID-19. However, evidence for the role of RM testing and RMT in the rehabilitation of patients with COVID-19 is still emerging.
Further research is needed to determine the most appropriate RM testing and RMT protocols for patients with COVID-19 and the effect of RMT on key functional outcomes.